<DOC>
	<DOCNO>NCT01301599</DOCNO>
	<brief_summary>This study design investigate comparison alpha blocker monotherapy 5-alpha-reductase inhibitor monotherapy follow combination therapy benign prostatic hyperplasia .</brief_summary>
	<brief_title>Comparison Between Alpha Blocker Monotherapy 5ARI Monotherapy Following Combination Therapy Benign Prostatic Hyperplasia ( BPH )</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>5-alpha Reductase Inhibitors</mesh_term>
	<mesh_term>Adrenergic alpha-Antagonists</mesh_term>
	<criteria>1 . Male age 45 year old ( upper limit age ) 2. patient underwent combination therapy alpha blocker 5 ARI 9 month 3 . IPSS â‰¤ 12 4 . Ability willingness correctly complete micturition diary questionnaire 5 . Capable understanding sign informed consent form full discussion research nature treatment risk benefit 1 . An anticholinergic antidiuretic start less 3 month prior screen 2 . Patients surgical treatment due LUTS 3 . Patients suspect neurogenic bladder disorder 4 . Patients cancer type include cancer prostate bladder 5 . Patients urethral stricture bladder neck contracture 6 . Patients suspicious chronic prostatitis/chronic pelvic pain syndrome 7 . Acute bacterial prostatitis le 6 month prior screen 8 . Symptomatic acute urinary tract infection ( UTI ) less 1 month prior screen 9 . Patients underwent prostatic biopsy le one month prior screen 10 . Patients unstable angina cerebral vascular disease le 6 month prior screen</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>alpha blocker</keyword>
	<keyword>5-alpha reductase inhibitor</keyword>
	<keyword>combination therapy</keyword>
</DOC>